Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 1279280, 10 pages
https://doi.org/10.1155/2017/1279280
Research Article

Pentoxifylline Regulates Plasminogen Activator Inhibitor-1 Expression and Protein Kinase A Phosphorylation in Radiation-Induced Lung Fibrosis

1Laboratory of Radiation Exposure & Therapeutics, National Radiation Emergency Medical Center, KIRAMS, Seoul, Republic of Korea
2Department of Pathology, Korea Cancer Center Hospital, KIRAMS, Seoul, Republic of Korea
3Molecular Imaging Research Center, KIRAMS, Seoul, Republic of Korea

Correspondence should be addressed to Sunhoo Park

Received 27 September 2016; Revised 30 December 2016; Accepted 19 January 2017; Published 27 February 2017

Academic Editor: Milton O. Moraes

Copyright © 2017 Jong-Geol Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. T. Milano, L. S. Constine, and P. Okunieff, “Normal tissue toxicity after small field hypofractionated stereotactic body radiation,” Radiation Oncology, vol. 3, no. 1, article 36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. D. W. Kamp, “Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited,” Chest, vol. 124, no. 4, pp. 1187–1190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Yamashita, K. Nakagawa, N. Nakamura et al., “Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors,” Radiation Oncology, vol. 2, article 21, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Muson, M. I. Schwarz, G. W. Hunninghake, and R. A. Musson, “Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future,” American Journal of Respiratory and Critical Care Medicine, vol. 160, no. 5, pp. 1771–1777, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Park, J.-Y. Ahn, M.-J. Lim et al., “Sustained expression of NADPH oxidase 4 by p38 MAPK-AKT signaling potentiates radiation-induced differentiation of lung fibroblasts,” Journal of Molecular Medicine, vol. 88, no. 8, pp. 807–816, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. W. A. Rosenkrans Jr. and D. P. Penney, “Cell-cell matrix interactions in induced lung injury. IV. Quantitative alterations in pulmonary fibronectin and laminin following X irradiation,” Radiation Research, vol. 109, no. 1, pp. 127–142, 1987. View at Publisher · View at Google Scholar · View at Scopus
  7. W.-T. Huang, P. K. Vayalil, T. Miyata, J. Hagood, and R.-M. Liu, “Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 46, no. 1, pp. 87–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. D. T. Eitzman, R. D. McCoy, X. Zheng et al., “Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene,” Journal of Clinical Investigation, vol. 97, no. 1, pp. 232–237, 1996. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Hattori, J. L. Degen, T. H. Sisson et al., “Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice,” Journal of Clinical Investigation, vol. 106, no. 11, pp. 1341–1350, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. Y.-P. Zhang, W.-B. Li, W.-L. Wang et al., “SiRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats,” Acta Pharmacologica Sinica, vol. 33, no. 7, pp. 897–908, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Meng, H. Squires, J. W. Stevens et al., “Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease,” Angiology, vol. 65, no. 3, pp. 190–197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. W. Stevens, E. Simpson, S. Harnan et al., “Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication,” British Journal of Surgery, vol. 99, no. 12, pp. 1630–1638, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-L. Lin, R.-H. Chen, Y.-M. Chen et al., “Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor,” Journal of the American Society of Nephrology, vol. 16, no. 9, pp. 2702–2713, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Berman and M. R. Duncan, “Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity,” Journal of Investigative Dermatology, vol. 92, no. 4, pp. 605–610, 1989. View at Publisher · View at Google Scholar · View at Scopus
  15. M. R. Duncan, A. Hasan, and B. Berman, “Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation,” Journal of Investigative Dermatology, vol. 104, no. 2, pp. 282–286, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. S. Muldowney III, Q. Chen, D. L. Blakemore, and D. E. Vaughan, “Pentoxifylline lowers plasminogen activator inhibitor 1 levels in obese individuals: a pilot study,” Angiology, vol. 63, no. 6, pp. 429–434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Hamama, S. Delanian, V. Monceau, and M.-C. Vozenin, “Therapeutic management of intestinal fibrosis induced by radiation therapy: from molecular profiling to new intervention strategies et vice et versa,” Fibrogenesis and Tissue Repair, vol. 5, no. 1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Kaya, R. Yazkan, M. Yildirim et al., “The relation of radiation-induced pulmonary fibrosis with stress and the efficiency of antioxidant treatment: an experimental study,” Medical Science Monitor, vol. 20, pp. 290–296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-L. Lefaix, S. Delanian, M.-C. Vozenin, J.-J. Leplat, Y. Tricaud, and M. Martin, “Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and α-tocopherol: An Experimental Study,” International Journal of Radiation Oncology Biology Physics, vol. 43, no. 4, pp. 839–847, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” FASEB Journal, vol. 22, no. 3, pp. 659–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-G. Lee, S. Park, C.-H. Bae et al., “Development of a minipig model for lung injury induced by a single high-dose radiation exposure and evaluation with thoracic computed tomography,” Journal of Radiation Research, vol. 57, no. 3, pp. 201–209, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. D. J. Loskutoff and J. P. Quigley, “PAI-1, fibrosis, and the elusive provisional fibrin matrix,” Journal of Clinical Investigation, vol. 106, no. 12, pp. 1441–1443, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Derynck, Y. Zhang, and X.-H. Feng, “Smads: transcriptional activators of TGF-β responses,” Cell, vol. 95, no. 6, pp. 737–740, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. P. F. Piguet, “Cytokines involved in pulmonary fibrosis,” International Review of Experimental Pathology, vol. 34, pp. 173–181, 1993. View at Publisher · View at Google Scholar · View at Scopus
  25. K.-Y. Hung, J.-W. Huang, C.-T. Chen, P.-H. Lee, and T.-J. Tsai, “Pentoxifylline modulates intracellular signalling of TGF-β in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis,” Nephrology Dialysis Transplantation, vol. 18, no. 4, pp. 670–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Hashimoto, Y. Gon, I. Takeshita, K. Matsumoto, S. Maruoka, and T. Horie, “Transforming growth factor- β1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 152–157, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Fine and R. H. Goldstein, “The effect of transforming growth factor-β on cell proliferation and collagen formation by lung fibroblasts,” The Journal of Biological Chemistry, vol. 262, no. 8, pp. 3897–3902, 1987. View at Google Scholar · View at Scopus
  28. Y.-M. Chen, K.-D. Wu, T.-J. Tsai, and B.-S. Hsieh, “Pentoxifylline inhibits PDGF-induced proliferation of and TGF-β-stimulated collagen synthesis by vascular smooth muscle cells,” Journal of Molecular and Cellular Cardiology, vol. 31, no. 4, pp. 773–783, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Schiller, F. Verrecchia, and A. Mauviel, “Cyclic adenosine 3′,5′-monophosphate-elevating agents inhibit transforming growth factor-β-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism,” Oncogene, vol. 22, no. 55, pp. 8881–8890, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Montminy, “Transcriptional regulation by cyclic AMP,” Annual Review of Biochemistry, vol. 66, pp. 807–822, 1997. View at Publisher · View at Google Scholar · View at Scopus